Fly News Breaks for May 20, 2019
REGN, SNY, NVS
May 20, 2019 | 16:31 EDT
Credit Suisse analyst Evan Seigerman started Regeneron Pharmaceuticals (REGN) with a Neutral rating and $336 price target. The analyst is concerned that Eylea could face "increasing headwinds" with the upcoming launch of Novartis' (NVS) brolucizumab. Further, he believes consensus estimates for the Sanofi (SNY) collaboration may be too high.
News For REGN;NVS;SNY From the Last 2 Days